Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated
nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in
Egypt. For decades the antiviral therapy of chronic HCV infection was based on the
administration of Interferon(IFN), initially alone and then in combination with Ribavirin
(RBV), but this regimen was effective in only 50% of patients with genotype 1, with
significant side effects.